On Tuesday, Organon & Co (NYSE: OGN) was 6.37% up from the session before settling in for the closing price of $7.06. A 52-week range for OGN has been $6.18 – $17.23.
Annual sales at Healthcare sector company slipped by -23.49% over the past five years. When this article was written, the company’s average yearly earnings per share was at -8.02%. With a float of $258.95 million, this company’s outstanding shares have now reached $259.98 million.
Organon & Co (OGN) Insider Updates
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Organon & Co stocks. The insider ownership of Organon & Co is 0.40%, while institutional ownership is 79.11%. The most recent insider transaction that took place on Nov 12 ’25, was worth 501,755. In this transaction Executive Chair of this company bought 65,400 shares at a rate of $7.67, taking the stock ownership to the 77,869 shares. Before that another transaction happened on May 14 ’25, when Company’s Director bought 12,469 for $8.07, making the entire transaction worth $100,591. This insider now owns 12,469 shares in total.
Organon & Co (OGN) Performance Highlights and Predictions
Going through the last 3-months fiscal report unveiled on the 12/31/2024, it has been observed that the corporation posted 0.9 earnings per share (EPS) during the time that was better than consensus figure (set at 0.87) by 0.03. Wall Street market experts anticipate that the next fiscal year will bring earnings of 1.0 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -8.02% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -0.78% during the next five years compared to -23.49% drop over the previous five years of trading.
Organon & Co (NYSE: OGN) Trading Performance Indicators
You can see what Organon & Co (OGN) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 1.20. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 0.31. Likewise, its price to free cash flow for the trailing twelve months is 2.51.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 1.92, a number that is poised to hit 0.76 in the next quarter and is forecasted to reach 3.93 in one year’s time.
Technical Analysis of Organon & Co (OGN)
Organon & Co (NYSE: OGN) saw its 5-day average volume 5.49 million, a positive change from its year-to-date volume of 4.78 million. As of the previous 9 days, the stock’s Stochastic %D was 30.27%.
During the past 100 days, Organon & Co’s (OGN) raw stochastic average was set at 26.03%, which indicates a significant decrease from 76.13% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.42 in the past 14 days, which was higher than the 0.37 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $8.76, while its 200-day Moving Average is $10.59. Nevertheless, the first resistance level for the watch stands at $7.66 in the near term. At $7.82, the stock is likely to face the second major resistance level. The third major resistance level sits at $8.09. If the price goes on to break the first support level at $7.23, it is likely to go to the next support level at $6.96. Assuming the price breaks the second support level, the third support level stands at $6.80.
Organon & Co (NYSE: OGN) Key Stats
There are 259,983K outstanding shares of the company, which has a market capitalization of 1.95 billion. As of now, sales total 6,403 M while income totals 864,000 K. Its latest quarter income was 1,602 M while its last quarter net income were 160,000 K.
